Abstract:Sarcoglycans are a group of single-pass transmembrane glycoproteins. In striated muscle, sarcoglycans interact with dystrophin and other dystrophin-associated proteins (DAPs) to form the dystrophin-associated glycoprotein complex (DGC). The DGC protects the sarcolemma from contraction-induced injury. Duchenne muscular dystrophy (DMD) is caused by dystrophin gene mutations. In the absence of dystrophin, the DGC is disassembled from the sarcolemma. This initiates a chain reaction of muscle degeneration, necrosis, inflammation and fibrosis. In contrast to human patients, dystrophin-null mdx mice are only mildly affected. Enhanced muscle regeneration and the up-regulation of utrophin and integrin are thought to protect mdx muscle. Interestingly, trace amounts of sarcoglycans and other DAPs can be detected at the mdx sarcolemma. It is currently unclear whether sub-physiological sarcoglycan expression also contributes to the mild phenotype in mdx mice. To answer this question, we generated delta-sarcoglycan/dystrophin double knockout mice (delta-Dko) in which residual sarcoglycans were completely eliminated from the sarcolemma. Interestingly, utrophin levels were further increased in these mice. However, enhanced utrophin expression did not mitigate disease. The clinical manifestation of delta-Dko mice was worse than that of mdx mice. They showed characteristic dystrophic signs, body emaciation and more macrophage infiltration. Their lifespan was reduced by 60%. Furthermore, delta-Dko muscle generated significantly less absolute muscle force and became more susceptible to contraction-induced injury. Our results suggest that sub-physiological sarcoglycan expression plays a critical role in ameliorating muscle disease in mdx mice. We speculate that low-level sarcoglycan expression may represent a useful strategy to palliate DMD.

Mutation in ε-Sarcoglycan Induces a Myoclonus-Dystonia Syndrome-Like Movement Disorder in Mice

A Novel Mutation Of The Epsilon-Sarcoglycan Gene In A Chinese Family With Myoclonus-Dystonia Syndrome

Transcriptomic disruption and functional hypoactivity in DYT-SGCE MGE-patterned inhibitory neurons

Sub-physiological Sarcoglycan Expression Contributes to Compensatory Muscle Protection in Mdx Mice.

Single Amino Acid Deletion in Transmembrane Segment D4S6 of Sodium Channel Scn8a (nav1.6) in a Mouse Mutant with a Chronic Movement Disorder

Miga-mediated endoplasmic reticulum-mitochondria contact sites regulate neuronal homeostasis

Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy

Whole exome sequencing identifies a novel homozygous MECR mutation in a Chinese patient with childhood-onset dystonia and basal ganglia abnormalities, without optic atrophy

Deletion of Brain Dystroglycan Recapitulates Aspects of Congenital Muscular Dystrophy

Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice

Dysregulation of Myosin Complex and Striated Muscle Contraction Pathway in the Brains of ALS-SOD1 Model Mice

Mice Carrying an Analogous Heterozygous Dynamin 2 K562E Mutation That Causes Neuropathy in Humans Develop Predominant Characteristics of a Primary Myopathy

On the Mental Status of Stargazer Mice

Lgi1 Null Mutant Mice Exhibit Myoclonic Seizures and Ca1 Neuronal Hyperexcitability

Face-valid phenotypes in a mouse model of the most common mutation in EEF1A2 -related neurodevelopmental disorder

Motor Neuron Degeneration in Mice That Express a Human Cu,Zn Superoxide Dismutase Mutation.

Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores

Home-cage behavior in the Stargazer mutant mouse

A mutation in F-actin polymerization factor suppresses the distal arthrogryposis type 5 PIEZO2 pathogenic variant in Caenorhabditis elegans

Patient-specific mutation of Dync1h1 in mice causes brain and behavioral deficits

Disruption of genes associated with Charcot-Marie-Tooth type 2 lead to common behavioural, cellular and molecular defects in Caenorhabditis elegans